Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.51 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.45 |
| ▸ | ITGAL | P20701 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28601501 | 1.00 | SYK (0.57) | SYKPDE10AMAP4K4MCHR1SUV39H2 | |
| SCHEMBL1351080 | 0.84 | SYK (0.63) | SYKCKS1BSKP1SKP2 | |
| SCHEMBL1351078 | 0.84 | SYK (0.63) | SYKCKS1BSKP1SKP2 | |
| SCHEMBL22499904 | 0.83 | PDE10A (0.58) | SYKPDE10AMAP4K4MCHR1SUV39H2 | |
| SCHEMBL29689781 | 0.83 | PDE10A (0.58) | SYKPDE10AMAP4K4MCHR1SUV39H2 | |
| SCHEMBL1351791 | 0.83 | SYK (0.64) | SYKPDE10AMAP4K4SUV39H2CKS1B | |
| SCHEMBL1351789 | 0.83 | SYK (0.64) | SYKPDE10AMAP4K4SUV39H2CKS1B | |
| SCHEMBL5873574 | 0.82 | MAP4K4 (0.61) | SYKPDE10AMAP4K4MCHR1SUV39H2 | |
| SCHEMBL24166014 | 0.81 | MAP4K4 (0.59) | PDE10AMAP4K4SUV39H2CKS1BSKP1 | |
| SCHEMBL22499926 | 0.80 | NOTUM (0.53) | SYKPDE10AMAP4K4SUV39H2CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| CN-113164461-A | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | SYK 4147/4885PDE10A 533/4885MAP4K4 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.